CIAM
STRO icon

Caitong International Asset Management’s Sutro Biopharma STRO Stock Holding History

Caitong International Asset Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Hold
0
– -$1 – 2486
2025
Q2 		– Hold
0
– – – 1936
2025
Q1 		– Sell
-35
Closed -$644 – 2515
2024
Q4 		$644 Buy
+35
New +$1.07K ﹤0.01% 1416

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Caitong International Asset Management's STRO Position: Q3 2025 in Review

Caitong International Asset Management held its Sutro Biopharma (STRO) position steady in Q3 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2486.

Caitong International Asset Management first reported a position in STRO in Q4 2024 and has held it in 1 quarter since. The position peaked at $644 in Q4 2024. 87 funds tracked by Wall St. Rank hold STRO as of Q3 2025.

  • Caitong International Asset Management held 0 shares of Sutro Biopharma worth $0 as of Q3 2025.
  • Caitong International Asset Management left its Sutro Biopharma share count unchanged in Q3 2025.
  • Sutro Biopharma made up ﹤0.01% of Caitong International Asset Management's portfolio in Q3 2025, its #2486 holding.
  • Caitong International Asset Management first reported a position in Sutro Biopharma in Q4 2024 and has held it in 1 quarter since.
  • Caitong International Asset Management's Sutro Biopharma position peaked at $644 in Q4 2024.
  • 87 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2025.

Based on Caitong International Asset Management's 13F filing for Q3 2025, filed 19 Nov 2025.